We’re powering innovation in pediatric clinical trial design and implementation—because half isn’t whole.
70% of the medicines given to children have only been studied in adults, and the majority of drugs used in children today are used off-label, without an adequate understanding of appropriate dose, safety, or efficacy.
Our industry is still guessing the clinical needs of children by settling for a fraction of what works in adults. We’re changing that.Read what it’s like being a sick kid in a grown-up world.
Pediatric expertise built on a foundation of analytics, partnerships, and experience.
Our Center for Pediatric Clinical Development functions as the central repository for our global pediatrics knowledge and focal point for our technical and strategic experts, equipping us to navigate the complexities and challenges of pediatric studies worldwide. We help our clients save time and resources by determining the feasibility and effectiveness of pediatric studies at every phase of a program. Our global experience allows us to develop and execute country-specific, customized recruitment and retention initiatives to help study teams meet or exceed goals.
As a part of our commitment to lead the way in pediatric research, we established our Pediatric Site Network (PSN). The PSN is a select group of internationally recognized pediatric centers and medical professionals from around the globe that share the common goal of bringing innovation to pediatric clinical design. Together, we are bringing new treatment options and access to novel medicines to the global pediatric patient population.Learn more about our best practices for recruitment and retention in pediatric trials.
Improving pediatric patient engagement.
Age-appropriate and culturally sensitive health resources help patients feel informed and remain engaged. That’s why we partnered with Jumo, an award-winning provider of educational content, and their clinical trial resources, to provide engaging content that transforms the patient experience.
Guiding pediatric studies through today’s complex regulatory landscape.
Testing drugs in children presents considerable scientific, clinical, ethical, technical, and logistical challenges. Lack of incentives for companies to develop and test drugs, lack of necessary technology to monitor these patients and assay very small amounts of blood, and lack of suitable infrastructure have all discouraged the testing of drugs in pediatric populations. Today, several legislative initiatives are in place to provide incentives or to require study plans in the pediatric population.See how we’re navigating today’s complex regulatory environment in pediatric studies.
Join PRA in China
The expertise of a global CRO + local know-how to deliver the highest caliber of clinical development services around the world.